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Abstract
Considering the key role of free amino acids in cell metabolism and their predictive role as biomarkers in 
breast cancer by alteration of their metabolic pathways, the purpose of this study was to identify and quantify 
the urine amino acids from healthy and breast cancer women, diagnosed in different histological stages. Using 
advanced LC-QTOF-(ESI+)-MS technique and EZ:faast kit, based on derivatization of free aminoacids, 16 amino 
acids from control and breast cancer groups, preliminarily classified in I-IIIA and II-IIIB stages were identified 
and quantified. The general LC/MS fingerprint showed significant quantitative differences, especially for serine, 
lysine, tyrosine and leucine and asparagine, which decreased or increased, respectively. The multivariate analysis 
(PCA) showed good discrimination between normal and pathological groups, with best discrimination by essential 
amino acids. Cluster Analysis confirmed three discrimination regions, a major BC group, the control-group and a 
minor five patient-group. When the mean values of essential and non-essential amino acids were represented, in 
relation to cancer stages, gradual decreases of non-essential and essential amino acids were observed, from stage 
I  to IIIA and from II to IIIB, in a parallel manner, non-essential amino acids having 3.5 times higher values than 
essential amino acids, the  decreases being more relevant for non-essential amino acids. Serine had the steepest 
decrease, followed by Tyrosine, both being recommended as good biomarker candidates. By ROC curves, lysine 
and isoleucine showed highest AUC values and confidence intervals to provide good diagnostic between healthy 
and BC groups. Nonetheless, in agreement with quantitative data and correlations with the breast cancer stages, 
serine and tyrosine had better potential to offer a good diagnosis and confidence in discriminating among different 
cancer progression stages.
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INTRODUCTION   
Cancer is the leading cause of death worldwide, 
breast cancer (BC) representing the most prevalent 
one in women, therefore new, rapid, sensitive and 
specific diagnostic methods are needed (Siegel et 
al., 2015). Recent advances in metabolomics have 
supported better understanding and enhanced 
clinical approach related to breast cancer early 
diagnosis and screening of potential biomarkers, 
able to discriminate among healthy and patho-
logical samples, as well as indicate disease 
stages (Oakman et al., 2012). Global and focused 
(targeted) metabolomics are the two approaches 
employed for biomarkers discovery, both of them 
offering added value to disease prognosis and 
diagnosis (Zhang et al., 2014). 
Amino acids are the main building blocks of 
proteins, with important roles as key metabolites 
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and metabolism regulators, being considered 
central compounds of altered metabolic networks 
during tumor growth. Specific abnormalities 
of amino acid metabolism and levels have been 
reported in cancer, including breast cancer (Wise 
and Thompson, 2010; Nagata et al., 2014). The 
tumor’s need for excessive consumption of amino 
acids for gaining energy (by carbohydrate and fat 
accumulation) results in a modification of amino 
acids concentration in blood (Fan et al., 2010, 
2012). Some studies have reported decreased 
concentrations of amino acids in biofluids, but others have reported increased concentrations, 
the turnover being related to the type of cancer 
and specific metabolic pathways (Lai et al., 2005; 
Denkert et al., 2006; Kim et al., 2010; Mustafa et al., 
2011; Poschke, et al., 2013; Armitage and Barbas, 
2014; Gu et al., 2015). The amino acid profile in 
breast cancer patients was performed especially 
in blood serum and plasma (Vissers et al., 2005; 
Okamoto et al., 2009; Jobard et al., 2014), fewer 
being focused on excreted amino acids through 
urine (Slupsky et al., 2010).
The fact that a higher turnover of amino acids 
is a characteristic feature of the cancer cell, a 
decreased concentration of amino acids in urine 
is expected due to their upregulation by amino 
acid transporters, which determine the excessive 
consumption of blood amino acids from blood, 
and a decreased release of free amino acids in urine (Dankert et al., 2008).
Urine is an ideal bio-medium for disease study 
because it is readily available, easily obtained and 
less complex than other body fluids (due to its 
reduced content of protein and long-term storage 
without any changes) (Zhang et al., 2012; Bouatra 
et al., 2013). In recent years, increased research 
on urine metabolic profile by optimised protocols 
was reported, for different cancer types, from 
prostate (Shamsipur et al., 2013), to gastric (Fan et 
al., 2012), bladder (Kim et al., 2010), lung (Mathé 
et al., 2014), ovarian, cervical and breast cancer 
(Woo et al. 2009; Slupski et al., 2010; Soydinc et 
al., 2012).
The most frequently used analytical 
techniques in metabolomic studies, for amino 
acid fingerprinting and quantification, ready to be 
introduced also in clinical screening are based on gas 
chromatography coupled with mass spectrometry 
(GC-MS), magnetic resonance spectrometry 
(MRS) but mostly, liquid chromatography with 
mass-spectrometry detection (LC-MS) (Patti et al., 
2012; Arnald et al., 2015). The latest technique is 
used with or without preliminary derivatisation 
of amino acids, which became a more powerful 
technique due to its higher sensitivity (Wilson et 
al., 2011; Le et al., 2014).
This paper reports a targeted metabolomic 
procedure based on technique LC-QTOF-(ESI+)-
MS technique applied for derivatised amino acids, 
to investigate the profile and concentrations of 
individual free amino acids in urine of thirty 
breast cancer women (histologically classified 
in 5 stages)  compared with five controls. By 
multivariate analysis  (Principal Component 
Analysis and Cluster Analysis), the discriminations 
between the groups  was done, identifying the 
amino acids as possible biomarkers for BC stage-
related diagnosis.
MATERIALS AND METHODS  
Urine sample collection
The urine samples were collected from 
thirty breast cancer patients (BC), preliminarily 
diagnosed by histological examination, and 
classified in five stages ( I-IIIA and II-IIIB), 
according to international classification (http://
www.nationalbreastcancer.org), and compared 
with five control urine samples from healthy 
patients (C). The main characteristics of the 
patients’ data are shown in Table 1.
LC-QTOF-(ESI+)-MS analysis
Volumes of 10 ml of normal spot urine 
were collected in sterile containers. After 
homogenisation, the samples were centrifuged 
by 5 minutes at 2000 rotations per minute. After 
centrifugation, the supernatant was stored at 
-200C until analysis. 
The amino acid fingerprinting and 
quantification was done by LC-QTOF-(ESI+)-MS 
technique and  the protocol  of EZ:faast amino 
acid free analysis kit as described previously by 
Romanciuc et al. (2014). The chromotographic separation was performed using a Thermo 
Scientific HPLC UltiMate 3000 system equipped 
with a quaternary pump delivery system Dionex 
and the mass spectra detection by a QTOF-(ESI+)-
MS Bruker Daltonics MaXis Impact device. 
The column used for amino acid derivatisation 
was an EZ:faast AAA-MS (Phenomenex) (250x3.0 
mm i.d.) using the solid phase extraction 
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(SPE), a step followed by derivatisation. Three 
internal standard solutions were used, namely 
homoarginine (HARG), methionine-D3 (MET-D3) 
and homophenylalanine (HPHE) that are not 
found in urine. The derivatisation agent was 
propyl chloroformate.
For LC separation, the mobile phase consisted 
of 10 mM ammonium formate in water (A) and 
10 mM ammonium formate in methanol (B). The 
flow rate was set at 0.250 ml/min, and the column 
temperature was 35oC. The gradient conditions 
used for the separation of amino acid derivatives 
were 68% B from 0 to 19 min followed by linear 
gradient to 93% B. The column was held at 93% 
B from 19.5 to 19.6 min., then returned to initial 
conditions 68% B from 19.6 min and allowed 
to equilibrate for 4.4 min. Run-to-run time was 
24 min. The injected volume was 5µL. Mass 
spectrometric conditions were: electrospray ion 
source (ESI) operated under positive ion mode, a 
nebulising gas pressure set at 2.8 bar, the drying 
gas flow at 12 L/min, the drying gas temp at 300ºC.
LC-MS data processing was done using 
successively the Base Peak Chromatogram, Dissect 
Chromatograms, Extracted Ion Chromatograms and 
QuantAnalysis (Bruker Daltonics software). Out of 
27 derivatised amino acids, a number of 16 amino 
acids were quantified as presented in Table 2.
Quantitative evaluation of amino acids and 
creatinine
First, a calibration curve for creatinine was 
built and validated at a concentration range from 
0.005 to 1 mg creatinine /ml (data not shown) 
and the mean correlation coefficient (r2) for the 
curve was 0.96. All amino acid concentrations 
were calculated and expressed as nanomols per 
mg creatinine.
Statistical analysis
Multivariate data analysis was conducted using 
Mann-Whitney U tests for the group discrimination, 
Unscrambler X 10.1 (CAMO Software AS, Norway) 
for Principal Component Analysis and Cluster 
Analysis (PCA) and Cluster analysis (CA). For the 
ROC analysis, based on individual mean values 
of each amino acid in BC and control groups, the 
MedCalc 15.8 Software was applied (Ostend, 
Belgium) in order to demonstrate their possible 
utility as markers for early diagnosis of breast 
cancer. The quantitative data for individual, non-
essential (NEAA) and essential (EAA) amino acids 
were calculated as mean ±standard deviation (SD) 
values for both breast cancer (BC) and control (C) 
groups.
RESULTS AND DISCUSSION   
Chromatographic amino acid separation and 
identification using Extracted Ion chromatogram 
(EIC).
From the initial base peak chromatogram 
obtained by LC-QTOF-(ESI+)-MS technique, 
including around 220 molecules (Fig.1 A and B), 
using Extracted Ion procedure, the EIC peaks 
corresponding to EAA and NEAA were  selected, 
namely 16 derivatised amino acids identified and 
quantified (as presented in Table 2) eliminating 
other non-proteinogenic amino acids or derivatives. 
Tab.1. Clinical characterisation of the groups of patients, with similar BMI (Body Mass Index), 
preliminarily classified by histological criteria in different stages
Data set Breast cancer (BC) ID BC Control (C)
Number 30 - 5
Age (Mean±SD) 57.53±12 - 45±3
BMI (Mean±SD) 26.97±4 - 26.56±7
Stage
I A 2 BC8, BC18 -
II A 5 BC2, BC4, BC7, BC16, BC32 -
III A 7 BC11, BC13, BC17, BC20, BC23, BC26, BC29 -II B 9 BC3, BC14, BC19, BC21, BC22, BC25, BC27, 
BC28, BC31
-III B 6 BC6, BC9, BC10, BC12, BC15, BC24 -
Uncharacterised 1 BC1 -
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All 16 amino acids quantified were identified 
in both groups. The general fingerprint was 
similar, the major differences were observed in 
lysine, arginine, valine, tryptophan, phenylalanine, 
tyrosine, which showed a decrease profile. 
The identification of the amino acids separated 
by EIC (Fig.1A/1B), according to their peak 
number, m/z value /molecular weight ([M+H+]/
MW) is presented in Table 2. 
Amino acid quantitification
The mean values of each amino acid (expressed 
in nmol/mg creatinine) ± standard deviations, for 
NEAA and EAA groups were calculated, as well 
as the ratios of values in C versus BC groups (C/
BC) and the statistical significance of differences 
(Table 3).
According to these data, one can notice general 
decreases of amino acid concentrations in BC 
group urines, in terms of total amino acids, as well 
essential (EAA) and non-essential (NEAA) ones. 
As individual concentrations, serine, glutamine, 
glycine, alanine and tyrosine were the major ones 
in the NEAA group (237-668 nmol/mg creatinine), 
while for the EAA group, lysine, hystidine and 
phenylalanine and tryptophan were major amino 
acids (from 119 to 270 nmol/mg creatinine)  in 
A 
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Fig.1. Comparative Extracted ion chromatograms (EIC) for derivatised amino acids separated from the control C 
(A) and BC (B) groups
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Tab. 2. The identification of the amino acids separated by EIC( Fig.1A/ 1B), according to their peak 
number, m/z value /molecular weight ([M+H+]/MW). *Internal standard 
Peak no.
Fig.1A/1B
[M+H+]/MW Aminocid Peak no.
Fig.1A/1B
[M+H+]/MW Aminocid
11/7 303/174.2 Arginine 130/139 370/155.1 Histidine26/16 317/188.2 Homoarginine* 132/140 246/117.1 Valine
37/30 275/146.2 Glutamine 140/147 318/147.1 Glutamic acid51/46 234/105.1 Serine 141/149 333/204.2 Tryptophan
57/52 260/131.1 Asparagine 159/169 260/131.2 Leucine
78/80 204/75.1 Glycine 163/170 294/165.2 Phenylalanine
89/94 218/89.1 Alanine 170/177 260/131.2 Isoleucine
97/99 347/132.1 Ornithine 193/193 308/179.2 Homophenylalanine*114/121 281/152.2 Methionine-d3* 206/203 396/181.2 Tyrosine122/136 361/146.1 Lysine
Tab. 3. Amino acid urine levels, expressed as mean values (x± SD, nmol/mg creatinine) in BC and Control 
(C) groups, their ratios, significance and tendency (increased or descreased mean values against 
controls)
Category Amino acid Abr.
BC
nmol/mg creatinine Cnmol/mg creatinine Ratio C/BC Significance(P-value) TendencyBC/C
Essent
ial ami
no acid
s 
(E
A
A
)
Histidine His 205.26±132 229.4±93 1.11 P>=0.05 Slight decrease
Leucine Leu 27.5±17 14.73±5 0.53 P=0.05 Strong IncreaseIsoleucine Ile 27.77±16 49.75±17 1.79 P=0.01 Decrease
Lysine Lys 89.78±73 270.12±60 3.03 P=0.001 Strong decreasePhenilalanine Phe 85.53±45 139.5±80 1.62 P>=0.05 Decrease
Tryptophan Tyr 82.34±48 119.69±58 1.45 P>=0.05 Decrease
Valine Val 53.71±27 75.7±26 1.4 P>=0.05 Dercrease
Total EAA 571.92 898.92 1.57 P>=0.05 DECREASE
Non-es
sential
 amino
 acids 
(N
E
A
A
)
Alanine Ala 237.36±135 310.21±113 1.3 P>=0.05 Decrease
Arginine Arg 18.62±12 27.04±10 1.45 P>=0.05 Decrease
Asparagine Asn 29.35±72 22.73±11 0.77 P>=0.05 Increase
Glutamine Gln 388.58±61 567.89±190 1.46 P>=0.05 Decrease
Glutamic acid Glu 14.92±9 17.38±12 1.16 P>=0.05 Slight Decrease
Glycine Gly 371.78±190 498.39±330 1.34 P>=0.05 Decrease
Serine Ser 418.64±245 668.33±199 1.59 P=0.01
Strong decrease
Tyrosine Tyr 122.82±76 203.48±81 1.66 P=0.04
Total NEAA 1602.11 2315.49 1.44 P>=0.05 DECREASE
Total AA 
(EAA+NEAA)
2174.022 3214.402 1.48 P>=0.05 DECREASE
Ratio NEAA/
EAA
2.80 2.57 0.91
Other Ornitine Orn 16.38±10 16.69±3 1.01 P>=0.05  - 
ROMANCIUC et al
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(Lys, Leu, Asn, Tyr and Ser) showed significant 
modifications. 
Lower concentrations of other urine 
amino acids in cancer patients were reported 
by other authors, such as alanine, glutamine, 
glycine, tryptophan, phenylalanine and valine, 
or methionine, isoleucine, phenylalanine and 
arginine (Okamoto et al., 2009), our results being 
consistent with these studies and others, mainly 
made on serum and plasma (Proenza et al., 2003; 
Vissers et al., 2005), fewer on urine ( Slupsky et al., 
2010; Miyagi et al., 2011; Barnes et al., 2014). 
Multivariate analysis 
Based on the quantitative data presented 
above (for the EAA, NEAA and TAA groups) for BC 
and Controls, the Principal Component Analysis 
(PCA) was performed, in order to discriminate 
differences among these groups, as presented in 
Fig 2.
The PCA graphics shows good discrimination 
between normal and pathological groups based on 
amino acid category, a very good discrimination 
when EAA were considered (PC1-64%), and 
lower discrimination potential where total amino 
acids and NEAA were considered (PC1-55% 
and 63%, respectively). In conclusion, the best 
discrimination was obtained between BC and 
controls, when EAA were considered.   
For a better view of grouping derived from 
PCA-EAA (Fig. 2, left) , Cluster Analysis (as shown 
in Fig.3) confirmed  three discriminating regions: 
a general BC group including 25 samples (below), 
a control-group (C) clustered in the middle and 
another small group of 5 BC  samples (above). 
Further investigation of the characteristics of the 5 samples is needed.  
C group, while in BC group, the mean values decreases around 35%. 
 Looking at individual amino acids, in the 
EAA group, all concentrations decreased except 
Leu. Strong and significant decrease against 
control was noticed for Lys (ratio C/BC=3.03, 
P=0.001), while for Leu, an increased ratio (C/
BC=0.53), and opposite to isoleucine which 
decreased (C/BC=1.79). In the NEAA group, also, 
except asparagine (C/BC=0.77), all amino acid 
concentrations decreased, more significantly 
for serine and tyrosine (C/BC=1.59 and 1.66, 
respectively).
These data are well correlated with specific 
amino acid pathways. It is known that out of the 
20 amino acids found in proteins, around 50% 
are NEAA, and the others (EAA) are supplied 
by the diet. Each amino acid undergoes its own 
metabolism and performs specific functions, so it 
is very difficult to trace their individual turnover. 
Nevertheless, free amino acid turnover is easier to 
follow, especially for some major representatives 
like Glu and Gln, which represents up to 50% from 
NEAA, in our case 25% in both BC and C groups. 
Since free amino acids are not stored but undergo 
different catabolic modifications by oxidative or non-oxidative deamination, transamination, 
urea cycle, leading to intermediates (such as 
Acetyl CoA) for carbohydrate and fatty acids/
sterols biosynthesis. In this context, the cancer 
cells are consuming larger quantities of amino-
acids, needed for their energetic survival, leaving 
lower quantities in biofluids, such as blood, but 
especially released in urine. Finally, this is a 
general explanation for decreased concentrations 
of almost all amino acids in BC patients. Of course, 
a deeper  discussion is needed, to explain which are 
the specific pathways where the five amino acids 
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Fig. 2. Comparative PCA-scores which allow the discrimination between the control  group and Breast 
cancer groups, independent of tumor stage, considering EAA, NEAA and total aminoacid concentrations
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progression, as reported in other studies, but 
using plasma amino acids (Okamoto et al., 2009). 
To have a better image of amino acid profile 
related to the different stages (IA-IIA and IIB-IIIB), 
mean values of total essential (EAA) and non-
essential amino acids (NEAA) were represented 
(Fig. 4-left); the mean values for the five amino 
acids (Ser, Tyr, Asn, Leu and Lys) (Fig. 4-right), 
in relation with their absolute values (presented 
in Table 3) from all tumor stages are presented 
comparatively.
 According to Fig.4-left, one can see gradual 
decreases of NEAA and EAA, from stage I to III (A) 
Dependence of amino acid concentrations on 
the BC tumor stage
In order to see the relevance of EAA, NEAA 
and individual amino acid concentrations for the 
tumor progression stage, and possible statistical 
correlations, the mean values of the sum of EAA, 
NEAA and the five amino acids with significant 
differences against controls, depending on the 
tumor stage, were represented graphically.
The main reason to see the dependence of 
amino acid concentrations on the BC tumor stage 
is the possibility to predict, from the individual 
or group levels of amino acids, the stage of tumor 
  
Fig. 3. Cluster analysis (CA), based on the Euclidian distances scale, for all 35 subjects, considering mean values 
of individual urine EAA as a complement of  PCA analysis.
Fig. 4. Left: Correlations between the tumor stages (I-IIIA, II-IIIB) and the mean values of Essential 
(EAA)  and non-essential amino acids (NEAA). Right: same correlations considering mean values of Lys, 
Leu (EAA), Asn, Ser and Tyr (NEAA).
ROMANCIUC et al
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and from II to IIIB, in a parallel manner, the NEAA 
having aprox. 3.5 times higher values than EAA. 
Comparatively, the modifications are more relevant 
in the NEAA group.
According to Fig. 4-right, Ser (the major amino 
acid) had the steepest decrease, followed by Tyr, 
related to the tumor stage and can be considered 
therefore good potential biomarkers. Between stage 
I-II A no differences are found, and there is a slow 
decrease between II and IIIA for the other amino acids 
( Asn, Leu and Lys). Comparatively, the decrease 
from stage II to IIIB is more significant. 
Therefore, considering similar observations 
(Myiagi et al., 2011), the decrease of  urine Serine 
and Tyrosine, as major NEAA, in early stages ( 
from IA to IIA or IIB and then IIIA or IIB) is a good 
reason to consider them as potential good biomarkers, 
significantly related to tumor progression. 
ROC Curves
To validate these five individual aminoacids, 
including also the isomer of Leu, Ileu,  the test by 
Reciver Opereting Characteristic Curve (ROC) was 
carried out, as presented  in Fig 5. 
The ROC curves of the cross-validated 
predicted class values were made for the 
individual amino acids which were identified to 
have significant modifications against controls (p 
<0.5).  
The good prediction as biomarker is related 
to higher AUC values, sensitivity and specificity. 
As presented in Fig.5,  AUC values (with 95% 
confidence interval-CI) were:
for Lys = 0.95, sensitivity 100%, specificity 90.3%, 
CI from 0.82 to 0.99
for  ILeu =0.84, sensitivity 74.19%, specificity 
100%, CI from 0.68 to 0.94 
for Ser = 0.80, sensitivity 77.42%, specificity 80%, 
CI from 0.64 to 0.91  
Fig. 5. ROC representation of tumor prognostic for six amino acids, as potential urine biomarkers (Leu, Ile, 
Lys, Ser, Asn, Ser and Tyr) for breast cancer
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for Tyr = 0.78, sensitivity 93.55%, specificity 60%, 
CI from 0.61 to 0.90
for Leu = 0.71, sensitivity 51.61%, specificity 
100%, CI from 0.54 to 0.85
for Asn = 0.63, sensitivity 32.26%, specificity 
100%, CI from 0.45 to 0.78
According to ROC parameters, Lys and Ileu 
showed highest AUC values and highest 95% 
confidence intervals to make good diagnostic 
between healthy and BC groups, while Ser and 
Tyr had slightly smaller AUC values, but a better 
potential to offer a good diagnostic with good 
confidence, in discriminating among different 
BC progression stages.  Leu and Asn had inferior 
predictibility value, they actually increased in BC 
group and had an opposite feature. This finding 
suggested that all four amino acids, namely Lys, Ileu, 
Ser and Tyr  have a good predictibility potential to 
be considered urine biomarkers for breast cancer 
diagnosis and tumor progression. A statistically 
significant decrease of Lysine was also signalled in 
a study conducted by Barnes et al. (2014). 
CONCLUSION   
Using targeted metabolomics, an optimized 
method to identify and quantify urine free amino 
acids as potential biomarkers for breast cancer 
and correlation to its stages was performed. 
Using advanced LC-QTOF-(ESI+)-MS 
technique and the specific advanced EZ:faast 
amino acid free analysis kit  based on derivatisation 
of free aminoacids, 16 urinary amino acids from 
control and breast cancer groups of patients were 
identified and quantified, preliminarily classified 
by histology in I-IIIA and II-IIIB stages. The general 
fingerprint of extracted Ion chromatograms was 
similar, with quantitative differences, especially 
for five amino acids: serine, lysine, isoleucine, 
tyrosine and asparagine, which generally showed 
decreases, but also increases (for asparagine and 
leucine). 
The multivariate analysis, as seen in the PCA 
graphics, shows good discrimination between 
normal and pathological groups, with best 
discrimination by EAA (PC1-64%), and lower 
discrimination potential by total amino acids and 
NEAA (PC1-55% and 63%, respectively). Cluster 
Analysis confirmed three discriminating regions, a 
major BC group of 25 samples, the control-group 
and a five BC patient-group. Further investigation 
of the characteristics of the 5 samples is needed. 
 To have a better image of amino acid profile 
related to the different stages (I-IIA and II-IIIB), 
the mean values of essential and non-essential 
amino acids were represented also for the five 
amino acids mentioned above.
There were observed gradual decreases of 
non-essential and essential amino acids, from 
stage I to IIIA and from II to IIIB, in a parallel 
manner, non-essential amino acids having 3.5 
times higher values than EAA. The decreases 
were more relevant for non-essential amino acids. 
Considering individual amino acid dynamic, Serine 
had the steepest decrease, followed by Tyrosine 
and best related to the tumor stage, so they are 
good biomarker candidates. Comparatively, the 
decrease from stage II to IIIB is more significant.
According to ROC curves, the aminoacids 
Lysine and Isoleucine showed highest AUC values 
and highest  95% confidence intervals to make 
good diagnostic between healthy and BC groups. 
Meanwhile, in agreement with quantitative data and 
correlations with the breast cancer stages, Serine 
and Tyrosine had better potential to offer a good 
diagnosis and confidence in discriminating among 
different BC progression stages, while Leucine and 
Asparagine, which increased in the breast cancer 
group, had inferior predictibility values.  
In conclusion, from the analysed urine 
samples, it is suggested that four free urine amino 
acids have a good diagnosis prediction value, 
namely Lys and Ileu, to discriminate between 
healthy and breast-cancer patients,  while  Ser 
and Tyr,  have high predictibility potential to be 
considered diagnosis biomarkers for different 
stages of breast cancer progression.  
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